MedTrace Logo

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

NCT00346866 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2008-08-05

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Conditions

Interventions

DRUG

anecortave acetate

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Patricia Zilliox · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2001-12-31
Completion
2001-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346866 on ClinicalTrials.gov